LifeMD, Inc. (LFMD)

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME's America's Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD's continued revenue growth, financial stability, and emerging leadership position in the health technology sector.

Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories.

TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.

LifeMD, Inc. ( LFMD ) Q3 2025 Earnings Call November 17, 2025 4:30 PM EST Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Sarah James - Cantor Fitzgerald & Co., Research Division Eduardo Martinez-Montes - H.C.

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.14 per share a year ago.

LifeMD Inc. (NASDAQ: LFMD) shares fell after the company released its third-quarter earnings report after Monday's closing bell, missing analyst estimates on the top and bottom lines.

Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.

LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care

Campbell and CO Investment Adviser LLC bought a new position in shares of LifeMD, Inc. (NASDAQ: LFMD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 26,361 shares of the company's stock, valued at approximately $359,000. Campbell and CO Investment Adviser LLC

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Acadian Asset Management LLC bought a new position in LifeMD, Inc. (NASDAQ: LFMD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 281,244 shares of the company's stock, valued at approximately $3,828,000. Acadian Asset Management LLC owned about 0.62% of LifeMD at the

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a virtual panel discussion titled “Creating a Scalable Virtual Primary Care and Obesity Health Platform” at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings.

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025.

Y Intercept Hong Kong Ltd bought a new position in shares of LifeMD, Inc. (NASDAQ: LFMD) during the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 60,049 shares of the company's stock, valued at approximately $818,000. Y Intercept Hong Kong Ltd owned 0.13% of LifeMD at the

Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD's Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD's Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In LifeMD To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) and reminds investors of the October 27, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.